Medicamen Biotech Q2FY19: PBT up by 51.93%; Overweight

Firstcall India Equity | Jan. 15, 2019, 12:28 p.m.


At the current market price of Rs. 435.25, the stock P/E ratio is at 37.39 x FY19E and 31.23 x FY2oE respectively.

Earning per share (EPS) of the company for the earnings for FY19E and FY2oE is seen at Rs. 11.64 and Rs. 13.94 respectively.

Net Sales and Operating Profit of the company are expected to grow at a CAGR of 23% and 46% over 2017 to 202oE respectively.

On the basis of EV/EBITDA, the stock trades at 21.10 x for FY19E and 18.08 x for FY2oE.

Price to Book Value of the stock is expected to be at 5.77 x and 4.87 x for FY19E and FY2oE respectively.

Hence, we say that, we are Overweight in this particular scrip for Medium to Long term investment.

blog comments powered by Disqus